NCT03500081

Solid Tumor Imaging MR-Linac (STIM Study)

Suspended Last updated 12 January 2026

What this trial tests

trial testing MRI Scan in Cancer in 295 participants. Suspended.

Timeline

2 October 2017

Primary endpoint
1 December 2027

1 December 2029

Quick facts

Lead sponsor	Medical College of Wisconsin
Status	Suspended
Study type	OBSERVATIONAL
Enrollment	295
Start date	2 October 2017
Primary completion	1 December 2027
Estimated completion	1 December 2029
Sites	1 location across United States

Drugs / interventions tested

• MRI Scan

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of MRI imaging and image fusion in radiation therapy has dramatically increased during the past decade. However, the existing MRI-imaging protocols, imaging software and pulse sequences are all optimized for diagnostic purposes. With the introduction of the MR-linac, there is a critical and imminent need to develop imaging protocols that build and adapt the existing imaging parameters within the scope of the FDA-approved software to acquire MRI images that have less geometric distortion and better spatial resolution.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer.
   Lorenz JW, Schott D, Rein L, Mostafaei F, et al · · 2019 · cited 8× · PMID 31259119 · DOI 10.7759/cureus.4510
2. Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions.
   Bryant JM, Doniparthi A, Weygand J, Cruz-Chamorro R, et al · · 2023 · cited 6× · PMID 37958374 · DOI 10.3390/cancers15215200
3. Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator.
   Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, et al · · 2023 · cited 5× · PMID 38035207 · DOI 10.1016/j.phro.2023.100504
4. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology.
   Hall WA, Kamgar M, Erickson BA, Ponce SB, et al · · 2021 · cited 2× · PMID 34611794 · DOI 10.1007/s10555-021-09993-z
5. Quantification and Dosimetric Impact of Normal Organ Motion During Adaptive Radiation Therapy Planning Using a 1.5 Tesla Magnetic Resonance-Equipped Linear Accelerator (MR-Linac).
   Wittmann D, Paulson ES, Banerjee A, Banla LI, et al · · 2025 · cited 1× · PMID 40291510 · DOI 10.1016/j.adro.2025.101758
6. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.
   Kamgar M, Hobbes GA, Davidson R, Dorbin D, et al · · 2026 · PMID 41134578 · DOI 10.1158/0008-5472.can-25-0018
7. Development of a Comprehensive Cardiac MRI Atlas of Half Fourier-Acquired Single-Shot Turbo Spin-Echo (HASTE) and 3D Balanced Steady-State Free Precession (bSSFP) Sequences Prospectively Acquired From a 1.5T MR-Linac.
   Schottstaedt AM, Paulson ES, Rubenstein J, Chen X, et al · · 2021 · PMID 34701962 · DOI 10.1016/j.ijrobp.2021.07.438
8. Quantification and Dosimetric Impact of Normal Organ Motion During Adaptive Radiation Therapy Plan Verification Using a 1.5 Tesla Magnetic Resonance Equipped Linear Accelerator (MR LINAC).
   Wittman D, Paulson ES, Eastwood D, Banerjee A, et al · · 2021 · PMID 34700566 · DOI 10.1016/j.ijrobp.2021.07.130